Sign up for our Oncology Central weekly news round-up

AACR19: surgery associated with increased survival in HER2+ Stage IV breast cancer patients

Written by Jenny Straiton, Future Science Group

Baculovirus Transduction of Human Mesenchymal Stem Cells

Photo credit: Volha Vshyukova HER2+ accounts for between 20–30% of all newly diagnosed Stage IV breast cancer patients. Recent advances in targeted treatments such as trastuzumab (Herceptin®) have led to improved survival for patients. Systematic therapies, such as chemotherapy or hormone therapy, taking the lead as a first line approach.Though surgery is often offered to patients, past research into whether it improves survival has given mixed results. In order to assess the effect of tumor resection on survival rates in HER2+ Stage IV breast cancer patients, researchers from the Loma Linda University Health (LLUH; CA, USA) and the University of California,...

To view this content, please register now for access

It's completely free